BUDGET IMPACT ANALYSIS OF APREMILAST IN PATIENTS WITH PSORIATIC ARTHRITIS IN THE ITALIAN SETTING

被引：0
|
作者：
Capri, S. [1 ]
Barbieri, M. [2 ]
Oskar, B. [3 ]
机构：
[1] LIUC Univ, Sch Econ & Management Cattaneo, Castellanza, Italy
[2] Univ York, Ctr Hlth Econ, York, N Yorkshire, England
[3] Celgene Corp, Milan, Italy
来源：
VALUE IN HEALTH | 2015年 / 18卷 / 07期
关键词：
D O I：
10.1016/j.jval.2015.09.2311
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
PMS67
引用
收藏
页码：A645 / A645
页数：1
相关论文
共 50 条
  • [31] Apremilast: A Review in Psoriasis and Psoriatic Arthritis
    Emma D. Deeks
    Drugs, 2015, 75 : 1393 - 1403
  • [32] Apremilast: A Review in Psoriasis and Psoriatic Arthritis
    Keating, Gillian M.
    DRUGS, 2017, 77 (04) : 459 - 472
  • [33] PREVALENCE OF PSORIATIC-ARTHRITIS IN ITALIAN PSORIATIC PATIENTS
    SALVARANI, C
    LOSCOCCO, G
    MACCHIONI, P
    CREMONESI, T
    ROSSI, F
    MANTOVANI, W
    BATTISTEL, B
    BISIGHINI, G
    PORTIOLI, I
    JOURNAL OF RHEUMATOLOGY, 1995, 22 (08) : 1499 - 1503
  • [34] IMPACT OF CLINICAL SPECIALTY SETTING ON DISEASE MANAGEMENT IN PATIENTS WITH PSORIATIC ARTHRITIS
    Boehncke, Wolf-Henning
    Horvath, Rudolf
    Dalkilic, Ediz
    Lima, Sonia A. L.
    Okada, Masato
    Hojnik, Maja
    Ganz, Fabiana
    Lubrano, Ennio
    ACTA DERMATO-VENEREOLOGICA, 2018, 98 : 20 - 21
  • [35] BUDGET IMPACT ANALYSIS OF CERTOLIZUMAB PEGOL FOR THE TREATMENT OF ACTIVE PSORIATIC ARTHRITIS IN GREECE
    Tzanetakos, C.
    Vassilopoulos, D.
    Kourlaba, G.
    Christou, P.
    Maniadakis, N.
    VALUE IN HEALTH, 2015, 18 (07) : A638 - A639
  • [36] TALTZ® (IXEKIZUMAB) FOR TREATMENT OF PSORIATIC ARTHRITIS IN THE UNITED STATES: A BUDGET IMPACT ANALYSIS
    Murage, M.
    Panchmatia, H.
    Patel, S.
    Birt, J.
    Gellet, A. M.
    Sprabery, A. T.
    Malatestinic, B.
    Atiya, B.
    Kern, S.
    Kadambi, A.
    VALUE IN HEALTH, 2020, 23 : S220 - S221
  • [37] IDELVION FOR THE TREATMENT OF HEMOPHILIA B: A BUDGET IMPACT ANALYSIS IN THE ITALIAN SETTING
    Villa, S.
    Castaman, G.
    Pradelli, L.
    VALUE IN HEALTH, 2017, 20 (09) : A549 - A549
  • [38] BASELINE CHARACTERISTICS OF PATIENTS WITH PSORIATIC ARTHRITIS INITIATED ON APREMILAST IN THE CORRONA PSORIATIC ARTHRITIS/SPONDYLOARTHRITIS (PSA/SPA) REGISTRY
    Meese, P. J.
    Rosenstein, E.
    Feng, H.
    Liu, M.
    Guerette, B.
    Teng, L.
    Rebello, S.
    Ogdie-Beatty, A. R.
    ANNALS OF THE RHEUMATIC DISEASES, 2018, 77 : 1039 - 1039
  • [39] Effectiveness and Drug Survival of Apremilast in 65 Patients With Psoriasis and/or Psoriatic Arthritis
    Garbayo Salmons, P.
    Exposito Serrano, V.
    Romani de Gabriel, J.
    Ribera Pibernat, M.
    ACTAS DERMO-SIFILIOGRAFICAS, 2022, 113 (05): : T532 - T535
  • [40] Is apremilast a promising treatment for psoriasis and psoriatic arthritis?
    Malara, Giovanna
    Miceli, Giovanni Francesco
    Arceri, Francesco
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2018, 79 (03) : AB171 - AB171
12345